Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%

MT Newswires Live

2025/03/31

Anteris Technologies (ASX:AVR) said its biomimetic DurAVR transcatheter heart valve (THV) has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.

Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.

The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.

Shares were down 6% in morning trade on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2523314249"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523314249\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523314249?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523314249","market":"sg","top_or_hot":-1,"title":"Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%","media":"MT Newswires Live","content":"<html><body><p> Anteris Technologies (ASX:AVR) said its biomimetic DurAVR transcatheter heart valve (THV) has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.</p><p>Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.</p><p>The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.</p><p>Shares were down 6% in morning trade on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 09:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Anteris Technologies (ASX:AVR) said its biomimetic DurAVR transcatheter heart valve (THV) has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.</p><p>Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.</p><p>The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.</p><p>Shares were down 6% in morning trade on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVR.AU","symbol_name":"ANTERIS TECHNOLOGIES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523314249","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523314249","pubTimestamp":1743384148,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anteris Technologies  said its biomimetic DurAVR transcatheter heart valve  has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.Shares were down 6% in morning trade on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVR.AU":"ANTERIS TECHNOLOGIES LTD","BK7126":"医疗保健用品","BK7007":"医疗保健设备"},"translate_title":"Anteris Technologies表示，超过100名患者接受了主动脉瓣狭窄医疗设备的治疗；股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVR.AU":0.9},"content_text":"Anteris Technologies (ASX:AVR) said its biomimetic DurAVR transcatheter heart valve (THV) has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.Shares were down 6% in morning trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}